Showing results (111-120 of 251) with videos related to

Sort By:
Pageof 26
ESMO Open|April 5, 2023
A randomized controlled trial of hand/foot-cooling by hilotherapy to prevent oxaliplatin-related peripheral neuropathy in patients with malignancies of the digestive systemA Coolbrandt, H Tobback, R Govaerts, et al.
European Journal of Cancer (Oxford, England : 1990)|January 25, 2011
Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803D Sargent, Q Shi, G Yothers, et al.
European Journal of Cancer (Oxford, England : 1990)|November 1, 1995
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study GroupD Cunningham, J R Zalcberg, U Rath, et al.
Gastroenterology|January 1, 1992
Effect of motilin on gastric emptying in patients with diabetic gastroparesisT L Peeters, E Muls, J Janssens, et al.
Acta Gastro-Enterologica Belgica|April 19, 2005
Analysis of Wnt/Beta catenin signalling in desmoid tumorsS Tejpar, G Michils, H Denys, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 23, 1998
A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancerE Van Cutsem, C Pozzo, H Starkhammar, et al.
The Journal of Thoracic and Cardiovascular Surgery|November 23, 2000
The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancerP Flamen, A Lerut, E Van Cutsem, et al.
ESMO Open|August 27, 2022
MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAFwt metastatic colorectal cancerJ Tabernero, A Grothey, D Arnold, et al.
ESMO Open|March 12, 2024
Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trialJ Tabernero, J Taieb, M Fakih, et al.
British Journal of Cancer|August 2, 2006
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinomaS Falk, A Anthoney, M Eatock, et al.
Pageof 26